Trial Profile

A Phase 1, Open-Label, Multiple Dose Study to Evaluate the Drug-Drug Interaction Potential Between Bemnifosbuvir/Ruzasvir and Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy®) in Healthy Adult Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 14 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bemnifosbuvir/Ruzasvir (Primary) ; Bictegravir/emtricitabine/tenofovir alafenamide (Primary)
Indications Hepatitis B; Hepatitis C; HIV-1 infections
Focus Pharmacokinetics
Sponsors Atea Pharmaceuticals

07 May 2025 According to an Atea Pharmaceuticals, Inc. media release, company announced that data from this trial were presented at the European Association for the Study of the Liver (EASL) Congress 2025 from May 7-10 in Amsterdam, Netherlands.
31 Jul 2024 Status changed from not yet recruiting to completed.
12 Apr 2024 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com